Implanon

Etonogestrel, the active ingredient in Implanon, is a progestin presented as a 68 mg subdermal implant (rod) for subcutaneous use. It prevents pregnancy by providing continuous hormonal contraception for women of reproductive age.

GNH USA supplies Implanon as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Implanon is a progestin‑based hormonal contraceptive that acts on the reproductive endocrine system to prevent pregnancy.

- Contraception: provides up to three years of reliable birth control after a single subdermal insertion. - Hormonal birth control: delivers a steady release of etonogestrel to suppress ovulation. - Reversible contraception: allows fertility to return promptly after removal of the implant.

Implanon may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Irregular vaginal bleeding or amenorrhea - Headache - Acne or skin changes - Weight gain - Insertion‑site pain or bruising - Breast tenderness

Serious or Rare Side Effects: - Infection at the insertion site - Implant migration or extrusion - Severe allergic reaction (anaphylaxis) - Deep vein thrombosis or pulmonary embolism - Ovarian cyst formation - Persistent abdominal pain or pelvic inflammatory disease

Before initiating Implanon therapy, several safety considerations should be reviewed.

- Medical evaluation: assess contraindications such as active liver disease or thromboembolic disorders. - Pregnancy status: confirm the patient is not pregnant before insertion. - Breastfeeding: discuss potential effects on milk production and infant exposure. - Drug interactions: review concomitant medications that may reduce contraceptive efficacy. - Smoking: advise cessation, especially for women over 35 years of age. - Store at ambient temperature below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Implanon can interact with medicines that influence hormone metabolism or plasma protein binding.

Major Interactions (Avoid): - Antiepileptic enzyme inducers (e.g., carbamazepine, phenytoin): may markedly reduce etonogestrel levels. - Rifampin or rifabutin: can lower hormonal efficacy, increasing risk of unintended pregnancy. - St. John’s wort: may decrease contraceptive effectiveness.

Moderate Interactions (Monitor Closely): - Certain antibiotics (e.g., tetracycline, metronidazole): possible modest reduction in hormone levels. - Antifungal agents (e.g., griseofulvin): may affect hormone metabolism. - Herbal supplements (e.g., ginseng, green tea extracts): monitor menstrual patterns and advise additional contraception if needed.